126 results
424B5
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Prospectus supplement for primary offering
4:02pm
over financial reporting audited by our independent registered public accounting firm pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 … and entities with relationships with us. The underwriters and their respective affiliates may also communicate independent investment recommendations
8-K
EX-5.1
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
4:00pm
independent investigation or verification of the matters referred to in the Certificate;
a certificate, documentation, notification, opinion or the like might
8-K
EX-1.1
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
4:00pm
Prospectus and the Prospectus, is an independent registered public accounting firm with respect to the Company within the meaning of the Securities Act … amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or verification, except
424B5
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Prospectus supplement for primary offering
4:40pm
, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant … with relationships with us. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color
S-3ASR
EX-4.6
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Automatic shelf registration
4:01pm
of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay … by it as provided in Section 1404 which, in the opinion of a nationally recognized firm of independent public accountants expressed in a written
S-3ASR
EX-23.3
r159wk7wt6u7
11 Sep 24
Automatic shelf registration
4:01pm
S-3ASR
EX-4.4
pmcrj0f bnb
11 Sep 24
Automatic shelf registration
4:01pm
S-3ASR
EX-5.1
hvy8ff8l9u9cd5chqsq
11 Sep 24
Automatic shelf registration
4:01pm
S-3ASR
1hz1lfrn
11 Sep 24
Automatic shelf registration
4:01pm
S-3ASR
EX-5.2
yo54e738
11 Sep 24
Automatic shelf registration
4:01pm
8-K
EX-99.2
mgh 8n1ic
10 Sep 24
Regulation FD Disclosure
7:08am
8-K
oqxgdcimi
25 Jun 24
Submission of Matters to a Vote of Security Holders
4:14pm
DEFA14A
jrxvj9ns q2gqj8vn9
20 May 24
Additional proxy soliciting materials
8:48pm
PRE 14A
gadtwho7m
26 Apr 24
Preliminary proxy
4:36pm
424B5
b74y6
24 Apr 24
Prospectus supplement for primary offering
8:53pm
8-K
EX-5.1
7wur7rf4z6hbr li6
24 Apr 24
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
9:26am